Orange Book product · Generic (ANDA)
SUPRAX
CEFIXIME
At a glance
Apr 10, 2007
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 10, 2007
19 yr 6 mo ago
Today
Pharmaceutical detail
Active ingredient
CEFIXIME
Strength
200MG/5ML
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
AB
Application
ANDA 065355
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of CEFIXIME
- 2013SUPRAXBrand (NDA)
NDA 202091 · LUPIN LTD
- 2012SUPRAXBrand (NDA)
NDA 203195 · LUPIN LTD
- 1989SUPRAXBrand (NDA)
NDA 050622 · LEDERLE
- 1989SUPRAXBrand (NDA)
NDA 050621 · LEDERLE
- 2026CEFIXIMEGeneric (ANDA)
ANDA 218691 · FDC LTD
- 2026CEFIXIMEGeneric (ANDA)
ANDA 217607 · AUROBINDO PHARMA LTD
- 2024CEFIXIMEGeneric (ANDA)
ANDA 206358 · FDC LTD
- 2021CEFIXIMEGeneric (ANDA)
ANDA 211775 · ALKEM LABS LTD
- 2018CEFIXIMEGeneric (ANDA)
ANDA 210574 · ALKEM LABS LTD
- 2017CEFIXIMEGeneric (ANDA)
ANDA 206144 · CHARTWELL RX
- 2017CEFIXIMEGeneric (ANDA)
ANDA 206938 · AJENAT PHARMS
- 2017CEFIXIMEGeneric (ANDA)
ANDA 206939 · AJENAT PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
